TECH Stock Analysis: Buy, Sell, or Hold?
TECH - Bio-Techne Corp.
$70.83
-0.17 (-0.24%)
▼
5d:
+0.18%
30d:
+42.31%
90d:
+32.44%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When TECH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: TECH is 9.1% above its trading range ($64.92). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: TECH is 9.1% above its trading range ($64.92). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$66.18
Based on 5.3% avg growth
INTRINSIC VALUE TODAY
$41.10
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TECH is currently trading at $70.83, which is considered extended relative to its 30-day fair value range of $49.42 to $64.92. From a valuation perspective, the stock is trading at a premium (Forward PE: 34.6) compared to its historical average (27.0). At these levels, the market is pricing in 8.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TECH is in a strong downtrend. The price is approaching resistance at $55.16. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TECH has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TECH is in a strong downtrend. The price is approaching resistance at $55.16. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TECH has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$49.42 -
$64.92
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.4%
All Signals
- BEARISH: Price extended above range (+9.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($69.08)
- NEUTRAL: PE elevated vs history but 8.6% growth expectation is conservative given 129% recent growth
Trading Range Analysis
30-Day Trading Range
$49.42 -
$64.92
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$47.22
Resistance Level
$55.16
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
34.63
Wall Street Target
$69.08
(-2.5%)
Revenue Growth (YoY)
-1.5%
Earnings Growth (YoY)
128.6%
Profit Margin
9.0%
Valuation Premium vs History
+8.6% premium
PE vs Historical
34.6 vs 27.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.6%
(market-implied from PE analysis)
1-Year Target
$76.92
(+9%)
2-Year Target
$83.54
(+18%)
3-Year Target
$90.72
(+28%)
3-Yr Target (if PE normalizes)
(PE: 35→27)
PE COMPRESSION
$70.73
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 34.6, Growth: 6.6%)
$85.74
(+21%)
Base:
(SPY PE: 21.8, Growth: 6.6%)
$53.93
(-24%)
Bear:
(PE: 18.5, Growth: 6.6%)
$45.84
(-35%)
📈
Valuation based on Current Earnings
Forward PE: 33.67 | Forward EPS (Implied): $2.10
Bull Case
$85.53
(+21%)
Analyst growth 15.0%, PE expands to 35.4
Base Case
$70.83
(0%)
Market implied 0.0%, PE stable at 33.7
Bear Case
$54.18
(-24%)
Severe decline -15.0%, PE contracts to 30.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 03, 2026 5:13 PM ET
Data refreshes hourly during market hours. Next update: 6:13 PM
Data refreshes hourly during market hours. Next update: 6:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TECH showing a specific setup today?
Insider Activity (6 Months)
2
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
BUY
2026-03-30
April McClain Delaney
SELL
2026-03-26
April McClain Delaney
SELL
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 57 HOLD |
